MiMedx Group, Inc.

NASDAQ:MDXG

Biotechnology

Healthcare
$3.18 +2.22%

+$0.08 today

Market cap
$464.04M
Beta
1.46
P/E (TTM)
17.8
EPS (TTM)
$0.21
52W Low $3.03High $7.99

Volume 1.51M

Average 1.55M

MDXG Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

MiMedx Group, Inc.NASDAQ: MDXG

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $17.37M rose 4.9% year over year, behind the +15.6% change in trailing-twelve-month cost of revenue. Sequentially, it fell 8.9% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.

Context

  • Cost of revenue amounted to 17.4% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +4.9% toward the trailing-twelve-month pace of +15.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.37M-8.9% QoQ
Last fiscal yearDec 2025
$73.01M+21.5% YoY
LTMMar 2026
$73.82M+15.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.9%——
1 year+21.5%——
3-year CAGR+14.8%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
73.01M USD
Year-over-year change
+21.5%
4-year CAGR
+16.5%

Cost of Revenue vs competitors

How MDXG compares with its peers on the latest reported figures

  • MDXG's LTM Mar 2026 cost of revenue of $73.82M is the 2nd highest of the 8 companies compared; the peer median is $9.48M.
  • Its year-over-year change of +15.6% is the 3rd highest of 8, against a peer median of +7.9%.
  • Cost of revenue amounts to 19.0% of revenue for MDXG, versus a peer median of 21.3%.
MDXG Competitors Peer median
Cost of Revenue for MDXG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$151.94M +37.2%+9.4%29.6%
MDXGMiMedx Group, Inc.LTM Mar 2026$73.82M +15.6%+14.8%19.0%
RCELAVITA Medical, Inc.LTM Mar 2026$13.48M +29.5%+28.4%18.6%
MDWDMediWound Ltd.LTM Mar 2026$11.64M -29.2%+0.9%80.4%
SMTISanara MedTech Inc.LTM Mar 2026$9.48M +7.9%+17.0%8.8%
BSEMBioStem Technologies, Inc.LTM Jun 2026$7.7M -17.8%+54.7%—
CELUCelularity Inc.LTM Dec 2025$6.36M -57.6%-31.4%24.0%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$298K +9.6%+5.1%2.0%
Peer median (excluding MDXG) $9.48M+7.9%+9.4%21.3%

Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue242.02M267.84M321.48M348.88M418.63M
Cost of Revenue39.63M48.32M54.63M60.07M73.01M
Gross Profit202.39M219.53M266.84M288.81M345.62M
Gross Margin83.6%82.0%83.0%82.8%82.6%
Research & Development9.93M12.7M12.67M12.34M15.1M
Selling, General & Admin194.85M220.85M216.3M216.39M266.19M
Operating Expenses209.44M234.25M229.73M229.94M281.29M
Depreciation & Amortization5.18M4.05M3.43M6.04M14.88M
EBITDA(1.89M)(10.69M)40.52M65.35M82.93M
EBITDA Margin-0.8%-4.0%12.6%18.7%19.8%
Operating Income(7.05M)(14.73M)37.12M58.87M63.89M
Operating Margin-2.9%-5.5%11.5%16.9%15.3%
Interest Income00004.72M
Interest Expense4.98M5.02M6.46M1.01M1.78M
Other Income / Expenses(5M)(5.02M)(6.48M)(1.57M)2.38M
Income Before Tax(12.05M)(19.75M)30.63M57.29M66.26M
Pre-Tax Margin-5.0%-7.4%9.5%16.4%15.8%
Income Tax Expense247K206K(36.81M)15.3M17.68M
Net Income(12.3M)(30.2M)67.44M42.42M48.58M
Net Margin-5.1%-11.3%21.0%12.2%11.6%
EPS (Basic)(0.09)(0.27)0.480.290.33
EPS (Diluted)(0.09)(0.27)0.380.280.32
Weighted Avg Shares110.35M112.91M116.5M146.98M147.79M
Weighted Avg Shares (Diluted)110.35M112.91M145.96M149.05M149.72M

MiMedx Group, Inc.

NASDAQ:MDXG

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.